uMed secures seed funding from Playfair Capital to expand its research network
Playfair Capital has backed the health technology firm in its latest funding round.
uMed operates a health and research technology platform that connects healthcare providers with clinical studies. The system automates patient identification and data collection to support medical research.
London health technology company uMed has secured seed investment from Playfair Capital. The fresh capital will be directed towards expanding the firm international research network.
Playfair Capital led the investment round, backing uMed's platform which combines electronic health records with targeted patient outreach. The technology allows healthcare providers to conduct clinical trials with minimal disruption to in-house staff.
Chief executive Matt Wilson welcomed the backing of the London-based investor, noting shared ambitions to make clinical studies more accessible. Chris Smith of Playfair Capital cited the team's expertise as a core driver for the partnership.
From the founder
"It is fantastic to be working with the Playfair Capital team who share our vision of making cutting edge research accessible to all healthcare providers and their patients"
Matt Wilson
Founder and CEO at uMed
Investor perspective
"We really believe that uMed and the team have the expertise and potential to fundamentally improve peoples’ lives and that patient engagement is the key to unlocking this sector’s potential"
Chris Smith
Managing Partner, Playfair Capital
Use of funds
- 01Expand into international markets
